The promise of revolutionary weight loss medications is colliding with stark real-world realities that could undermine their long-term health impact. While GLP-1 receptor agonists like semaglutide and tirzepatide demonstrate remarkable efficacy in controlled clinical trials, their effectiveness depends entirely on patients actually taking them consistently over time.
This comprehensive analysis of 17.9 million commercially insured Americans reveals concerning patterns in medication persistence for high-potency GLP-1 drugs prescribed specifically for weight loss between 2021 and 2024. The study tracked treatment continuation rates among patients without diabetes who newly initiated either Wegovy or Zepbound, examining how supply shortages and evolving market dynamics affected long-term adherence patterns. The research methodology excluded diabetic patients to isolate weight-loss-specific usage patterns, providing the clearest picture yet of how these medications perform outside clinical trial conditions.
This persistence gap represents a critical challenge for obesity medicine. Unlike diabetes medications where immediate health consequences create strong adherence incentives, weight loss drugs face unique barriers including cost concerns, side effect tolerance, and lifestyle integration difficulties. The timing coincides with well-documented supply shortages that began disrupting access in 2021, potentially creating discontinuation patterns that persist even after availability improves. For clinicians and patients investing in these expensive therapies, understanding realistic expectations for long-term adherence becomes essential for treatment planning. The findings suggest that current approaches to supporting medication persistence may be insufficient to realize the full population health benefits these drugs promise for addressing obesity-related chronic disease.